Committee For Advanced Therapies (CAT) Elects Chair And Vice-chair, Europe

February 16, 2009 at 2:00 pm Leave a comment


The European Medicines Agency’s (EMEA) new Committee for Advanced
Therapies (CAT) has elected Christian Schneider, from Germany, as chair
and Anneli Salmikangas, from Finland, as vice-chair for a three-year
mandate starting on 12 February 2009.



The CAT is a multidisciplinary committee, bringing together some of the
best available experts in Europe to assess the quality, safety and
efficacy of advanced therapy medicinal products (ATMPs) and to follow
scientific developments in the field.



Setting out his priorities for the next three year, Dr Schneider said:
“Our common goal is to establish the CAT as a strong and internationally
highly recognized independent committee. A committee that fosters
innovative medicines gathers scientific expertise and skills, whilst it
collaborates effectively with the other scientific committees at the
EMEA to perform top-level assessment in the best interest of patients”.



Dr Schneider and Dr Salmikangas have contributed to the work of the EMEA
with their expertise over many years. Dr Schneider is a member of the
Committee for Medicinal Products for Human Use (CHMP), the Scientific
Advice Working Party (SAWP) and he also chairs the Biosimilar Medicinal
Products Working Party (BMWP).
Dr Salmikangas is the chair of the EMEA’s Cell-based Products Working
Party (CPWP) and a member of the Biologics Working Party (BWP).



Notes:




1. Dr Schneider is a physician by training, specialising in immunology
and rheumatology. He is currently head of division for EU
cooperation/microbiology at the Paul-Ehrlich-Institut (PEI), in Langen,
Germany. His areas of expertise include: quality and safety of
biological medicines, including ATMP; clinical trials and risk
mitigation strategies for first-in-man clinical trials; non-clinical
development of biotechnology-derived medicinal products; unwanted
immunogenicity of therapeutic proteins; concepts for comparability
exercise for biotechnological medicinal products.




2. Dr Salmikangas is a biochemist. She is Senior Researcher, responsible
for marketing authorisations of biological medicinal products at the
National Agency for Medicines in Finland. She is also Associate
Professor in Biochemistry, University of Helsinki. Her area of expertise
is focused on cell and molecular biology of various inherited diseases.




3. An overview of the role and responsibilities, membership and other
details about the Committee for Advanced Therapies is available
here.




4. More information on the work of the EMEA in the area of advanced
therapies is available
here.




5. This press release, together with other information on the work of
the EMEA, can be found on the EMEA website: http://www.emea.europa.eu




EMEA

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

The American Diabetes Association Provides Tips For Heart Healthy Eating First Use Of New Subcutaneous Heart Monitor

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,554 hits

%d bloggers like this: